Press Releases BioSenic SA

Equities

BIOS

BE0974280126

Market Closed - Euronext Bruxelles Other stock markets 11:35:25 2024-04-26 am EDT			5-day change	1st Jan Change
0.0156 ^EUR	-4.29%		-20.41%	-74.51%

Apr. 11	Biosenic: launch of a debt restructuring plan	CF
Mar. 12	Biosenic S.A. Releases Details of Optimized Administration Approach Ahead of Planned Phase 3 Trial of OATO for Chronic Graft-Versus-Host Disease	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioSenic publishes on its website the restructuring plan submitted to the Enterprise Court of Nivelles	Apr. 26	GL
BioSenic postpones its annual general meeting of the shareholders and provides temporary non-audited financial figures for 2023	Apr. 24	GL
BioSenic postpones its annual general meeting of the shareholders and provides temporary non-audited financial figures for 2023	Apr. 24	AQ
BioSenic S.A. : Transparency notifications received from François Rieger	Apr. 18	GL
BioSenic provides further information on its restructuring plan	Apr. 12	GL
BioSenic : summary bonds refinancing_20240411	Apr. 12	PU
BioSenic and its restructuring practitioner (Me Yves Brulard) submit a global restructuring plan covering the years 2024-2030 to the Enterprise Court of Nivelles	Apr. 11	GL
BioSenic and its restructuring practitioner (Me Yves Brulard) submit a global restructuring plan covering the years 2024-2030 to the Enterprise Court of Nivelles	Apr. 11	AQ
BioSenic presents successful preclinical data on its ATO medication for controlling key symptoms at the 2024 Systemic Sclerosis World Congress	Mar. 20	GL
BioSenic releases details of optimized administration approach ahead of planned Phase 3 trial of OATO for chronic graft-versus-host disease	Mar. 12	GL
BioSenic raises €500,000 in private placement of new shares with established new investors	Feb. 02	GL
BioSenic provides support to forthcoming European conference on graft-versus-host disease	Jan. 31	GL
BioSenic patent granted in Canada for broader protection of ATO therapeutic platform	Jan. 30	GL
BioSenic presents new Phase 3 data on JTA-004 to treat severe osteoarthritis pain at the 2024 OARSI World Congress	Jan. 25	GL
BioSenic presents new Phase 3 data on JTA-004 to treat severe osteoarthritis pain at the 2024 OARSI World Congress	Jan. 25	AQ
BioSenic files for additional patent protection following new clinical evidence of efficacy for JTA-004 in osteoarthritis	Jan. 23	GL
BioSenic S.A. : Transparency notifications received from François Rieger	Jan. 15	GL
BioSenic reaches agreement on a binding term sheet with Phebra PTY Ltd. with respect to the development of the first oral formulation of arsenic troxide for cGvHD treatment	Jan. 15	GL
BioSenic appoints Dr Carole Nicco as Chief Operating Officer in addition to Chief Scientific Officer	Jan. 10	GL
BioSenic appoints Dr Carole Nicco as Chief Operating Officer in addition to Chief Scientific Officer	Jan. 10	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases BioSenic SA

Equities

BIOS

BE0974280126

Press Releases

Filters